Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AVROBIO, Inc.
  6. News
  7. Summary
    AVRO   US05455M1009


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1

10/19/2021 | 07:00am EST

AVROBIO, Inc. reported new safety data from the first lentiviral gene therapy clinical trials for Fabry disease and Gaucher disease, as well as new high-resolution cellular data providing insights into the mechanisms of action of its gene therapies. The data are being presented at the virtual 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 19-22, 2021. Fabry disease clinical trial safety data reinforce predictable and generally consistent safety profile New safety data from the first eight adult patients dosed in the Phase 2 FAB-GT trial and the five adult patients dosed in the investigator-sponsored Phase 1 trial show no adverse events (AEs) or serious adverse events (SAEs) related to drug product AVR-RD-01. The AEs and SAEs experienced by trial participants to date in the two trials have been generally consistent with myeloablative conditioning, protocol-mandated drugs, underlying disease or pre-existing conditions. Of all safety events reported to date, 4% were classified as SAEs (n=11), consisting of nausea, vomiting, dehydration, fever, febrile neutropenia and mucosal inflammation, all of which resolved without clinical sequelae. These safety data are from patients in the FAB-GT study with a mean post-gene therapy follow up of 16 months (range: 2-38 months) and the Phase 1 study with a mean post-gene therapy follow-up of 39 months (range: 29-54 months). Safety data from the ninth patient recently dosed in the FAB-GT study are still being analyzed, but preliminary data are consistent with the overall safety profile. With AVROBIO’s Bu90-Target Concentration Intervention (TCI) conditioning regimen, patients receive four daily doses of the conditioning agent busulfan, each adjusted to target a cumulative area under the curve of 90 mg x hr/L. This targeted dosing is intended to maximize busulfan’s ability to make space in the bone marrow for the genetically modified stem cells to engraft, while minimizing the risk of out-of-range toxicity. AVROBIO is also working with clinicians to develop comprehensive care guidelines designed to help gene therapy care teams further proactively mitigate or prevent potential side effects. Six of the 14 Fabry disease patients in the trials have been treated using AVROBIO’s proprietary plato® gene therapy platform, which includes a optimized lentiviral vector, proprietary tag technologies, proprietary analytical techniques and Bu90-TCI. The platform’s closed, automated manufacturing platform is designed to bring gene therapy to patients worldwide. The safety data cut-off date for the Phase 1 trial was July 26, 2021, and for the FAB-GT trial was Aug. 20, 2021. Gaucher disease type 1 clinical data at 12+ months show no unexpected safety events:- New safety data from the first patient dosed in the Phase 1/2 Guard1 trial of AVR-RD-02 show no SAEs and no AEs to date related to drug product more than 14 months post-treatment. Reported AEs for this patient, who was treated with investigational AVR-RD-02 incorporating key elements of AVROBIO’s proprietary plato® gene therapy platform, have been consistent with myeloablative conditioning, protocol-mandated drugs, underlying disease and pre existing conditions. The safety data cut-off date was Aug. 31, 2021.

ę S&P Capital IQ 2021
All news about AVROBIO, INC.
11/24Avrobio Reports No Adverse Effects for Gene Therapies AVR-RD-01, AVR-RD-02
11/24AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Dat..
11/24AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safet..
11/19Morgan Stanley Downgrades AVROBIO to Equal-Weight From Overweight, Adjusts Price Target..
11/09Jasper Therapeutics Teams Up with Avrobio To Study JSP191 On Fabry, Gaucher Disease Pat..
11/09Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as..
11/09AVROBIO to Present at Two Upcoming Investor Conferences in November
11/08AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
11/08AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
More news
Analyst Recommendations on AVROBIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -124 M - -
Net cash 2021 160 M - -
P/E ratio 2021 -1,28x
Yield 2021 -
Capitalization 168 M 168 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 121
Free-Float 97,1%
Duration : Period :
AVROBIO, Inc. Technical Analysis Chart | AVRO | US05455M1009 | MarketScreener
Technical analysis trends AVROBIO, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 9
Last Close Price 3,71 $
Average target price 22,88 $
Spread / Average Target 517%
EPS Revisions
Managers and Directors
Geoff MacKay President, Chief Executive Officer & Director
Erik Ostrowski Chief Financial Officer & Treasurer
Bruce Lee Booth Chairman
Christopher Mason Chief Scientific Officer
Kim Raineri Chief Manufacturing & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
AVROBIO, INC.-72.45%168
BIONTECH SE331.48%84 953
WUXI APPTEC CO., LTD.30.33%66 734